Novigenix
GENEVA, SWITZERLAND / ACCESSWIRE / January 17, 2024 / With cancer projected to escalate to 29 million cases by 2040[1], Novigenix, a pioneer in AI healthcare solutions, is rewriting the rules of cancer care. Their newest innovation, LITOSeek™, is primed to reshape drug development, offering a transformative leap forward.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Personalized Cancer Treatment: Breaking Barriers
Every cancer is as unique as the person it affects. Tumors are in continuous dynamic interplay with the patient's immune defenses and are adept at subverting and escaping immune control. Novigenix is on a mission to improve the cancer treatment landscape, leveraging advanced AI and RNA analysis from a routine blood draw to provide more precise insights into patient immune responses to cancer treatments, compared to conventional DNA liquid biopsies that evaluate tumor evolution through circulating tumor DNA (ctDNA). Insights into the precise dynamic of patient immune response thus pave the way for superior therapeutic discoveries in the field.
Empowering Biopharma: Unveiling LITOSeek™ at Precision Medicine World Conference
On January 24th at the Precision Medicine World Conference in Silicon Valley, Novigenix will debut LITOSeek™, a groundbreaking solution designed to expedite drug development for biopharma companies.
AI and RNA Analysis: Pioneering Healthcare Transformation
With a decade-long track record, Novigenix successfully launched Colox® blood test in Switzerland, powered by AI and RNA analysis to detect early-stage colon cancer, marking a significant departure from invasive colonoscopy procedures. By aggregating data from diverse colon cancer patients, Novigenix identified immune system biomarkers crucial for early-stage detection, enhancing treatment outcomes.
Dr. Brian Hashemi, Novigenix's CEO and Chairman, emphasized, "Our experience with Colox® underscores the potential of AI RNA analysis. Ongoing studies across various cancer types have fuelled our Knowledge Base to uncover comprehensive sets of biomarkers via liquid biopsy and AI RNA analysis. Our validated immunotherapy response biomarkers provide early prediction of patient response and we invite biopharma companies to leverage our platform for more efficient and effective drug development."
Professor Pedro Romero, M.D. Chief Medical & Scientific Officer of Novigenix, and Founding Chief Editor of the Journal of Immunotherapy of Cancer, highlights the importance of patient immune response in the development of novel therapies: "AI RNA analysis is poised to revolutionize healthcare, accelerating conventional experimental drug development with data-driven precision immune response prediction. By swiftly analyzing systemic immune responses, AI compresses analysis times, expediting traditional drug development and powering discovery of novel therapy targets."
A Team Dedicated to the Future of Cancer Care
With over 20 Ph.D.-level scientists focused on the development of the LITOSeek™ platform and advancing next-generation liquid biopsy solutions, Novigenix is pioneering precision immunology to help transform cancer treatment paradigms for better patient outcomes.
#Ends#
[1] https://canceratlas.cancer.org/the-burden/the-burden-of-cancer/
Contact Information
Edwin Shankar
edwin.shankar@leidar.com
SOURCE: Novigenix
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESSWIRE
Subscribe to releases from ACCESSWIRE
Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESSWIRE
Polaris Renewable Energy Successfully Settles USD 175 Million Bond Issue4.12.2024 16:05:00 CET | Press release
TORONTO, ON / ACCESSWIRE / December 4, 2024 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company") announces that it has successfully settled a previously announced private placement of USD 175 million senior secured green bonds. The bonds will have a tenor of five years and a fixed coupon rate of 9.5% percent per annum, with interest payable in semi-annual instalments. Furthermore, the Green Bond will include a tap feature, allowing for access to an additional USD $50 million in funding for potential future uses. The bond issue is rated BB- by S&P Global Ratings and is issued under the Company's green finance framework with second-party opinion from Morningstar Sustainalytics. Marc Murnaghan, Chief Executive Officer of Polaris comments: "We are very pleased to successfully settle this inaugural bond issue with strong interest from a wide set of international investors. The bond optimizes the Company's capital structure and secures financing for further growth and incre
Maxon One Winter Release Brings Holiday Cheer from Concept to Render4.12.2024 10:20:00 CET | Press release
Defy cookie-cutter conventions, create the magic of snowfall, and craft festive figures with updates in Cinema 4D, ZBrush, Red Giant and Redshift; master chef of digital delectables Patrick 4D gets in on the fun with gingerbread delights for all BAD HOMBURG, GERMANY / ACCESSWIRE / December 4, 2024 / Maxon, maker of powerful, approachable software solutions for content creators working in 2D and 3D design, motion graphics, visual effects, and more, today released updates across its Maxon One product suite, with new features in Cinema 4D, Redshift, ZBrush and ZBrush for iPad, and Red Giant. The release fulfills artists' holiday wishlists with new capabilities that enhance everyday workflows and improve quality of life for artists, animators, VFX professionals, and studios. Image courtesy of Patrick 4D Whether it's crafting unique models using brand new Cinema 4D Booleans that give cookie-cutter a whole new meaning or bringing a dazzling snowfall to life with Cinema 4D Particles, Maxon On
Autobrains and JOYNEXT Revolutionize Smart Camera Solution Powered by Autobrains’ Affordable Safety ADAS Software4.12.2024 04:00:00 CET | Press release
Driving the Future of Safety: Cost-Effective, AI-Powered ADAS Solutions for Global OEMs MUNICH, GERMANY | DRESDEN, GERMANY | TEL AVIV, ISRAEL / ACCESSWIRE / December 4, 2024 / Autobrains, a leader in automotive artificial intelligence (AI), has joined forces with JOYNEXT, a global automotive Tier-1 supplier and development partner to renowned car manufacturers for over 20 years, to offer their groundbreaking Smart Camera ADAS solution. The camera hardware and optimized control software, provided by JOYNEXT, is powered by Autobrains' Affordable Safety ADAS software. The single-box Smart Camera solution, optimized for cost-effective Advanced Driver Assistance Systems (ADAS), was designed to meet the evolving needs of global Original Equipment Manufacturers (OEMs). This compact system simplifies integration, reduces costs, and ensures regulatory compliance without sacrificing performance. With ever increasing global regulations, smart cameras are a must-have in new build vehicles. The joi
IXOPAY and Aperia Compliance Merge to Extend Advanced Payment Data Security to Merchant Acquirers and Merchants of All Sizes, Worldwide4.12.2024 00:00:00 CET | Press release
Merger combines IXOPAY's enterprise-grade capabilities in payment orchestration and tokenization with Aperia Compliance's PCI DSS Level 3 and 4 solutions. TULSA, OKLAHOMA / ACCESSWIRE / December 4, 2024 / IXOPAY, a leading payments technology provider handling more than $35 billion in payment volume through its enterprise-grade payment orchestration platform, announced today that it has merged with Aperia Compliance, a subsidiary of Aperia Solutions and a leading firm in Payment Card Industry Data Security Standard (PCI DSS) data validation and risk management. Serving more than 100 merchant acquirers, Aperia Compliance will operate as "Aperia Compliance, an IXOPAY company." IXOPAY offers enterprise-grade PCI DSS Level 1 and 2 solutions powered by advanced tokenization. Paired with Aperia Compliance's robust PCI DSS Level 3 and 4 solutions-including PCI Apply 4.0 and the new 6.4.3 product-the combined offering aims to deliver a scalable, end-to-end solution enabling merchants, independ
Japan Maritime Defense Force Selects SeaGuardians From GA-ASI3.12.2024 14:00:00 CET | Press release
SAN DIEGO, CA / ACCESSWIRE / December 3, 2024 / The Japan Maritime Self-Defense Force (JMSDF) has selected the General Atomics Aeronautical Systems, Inc. (GA-ASI) SeaGuardian® Remotely Piloted Aircraft (RPA) systems for its Long Endurance Unmanned Aerial Vehicle program. This follows JMSDF use of SeaGuardian since May 2023 as part of its Medium-Altitude, Long Endurance (MALE) RPA System Trial Operations Project. SeaGuardian has been used by JMSDF to conduct various tests including whether unmanned aircraft can supplant some of the missions currently accomplished with manned aircraft. SeaGuardian is a MALE RPA system that can fly for 24 hours or more, depending on the configuration. GA-ASI has strengthened its Maritime Wide Area Surveillance (MWAS) for Japan with Optix+, which gathers information from the SeaGuardian sensors, as well as other data sources, displaying the full picture of surveillance information for its operator. This functionality makes it easy to task and direct its In
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom